These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34119352)

  • 21. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
    Liao YP; Jiang JL; Zou WY; Xu DR; Li J
    World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
    Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
    Gu G; Yang JZ; Zhang JQ; Sun LX
    Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
    Miller JS; Warren EH; van den Brink MR; Ritz J; Shlomchik WD; Murphy WJ; Barrett AJ; Kolb HJ; Giralt S; Bishop MR; Blazar BR; Falkenburg JH
    Biol Blood Marrow Transplant; 2010 May; 16(5):565-86. PubMed ID: 20152921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
    Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The transplantation of hematopoietic stem cells after non-myeloablative conditioning: a cellular therapeutic approach to hematologic and genetic diseases.
    Maris M; Storb R
    Immunol Res; 2003; 28(1):13-24. PubMed ID: 12947221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies.
    Luo Y; Zeng HQ; Shen Y; Zhang P; Lou SF; Chen L; Deng JC
    Leuk Res; 2016 Sep; 48():6-10. PubMed ID: 27416327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
    Front Immunol; 2019; 10():1997. PubMed ID: 31507601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Use of Total Body Irradiation in Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation.
    Jung J; Lee H; Suh YG; Eom HS; Lee E
    J Korean Med Sci; 2021 Mar; 36(8):e55. PubMed ID: 33650334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
    Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
    Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in second hematopoietic stem cell transplantation.
    Yan S; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1428101. PubMed ID: 39044835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
    Petrovic A; Hale G
    Expert Rev Clin Immunol; 2011 Jul; 7(4):515-25; quiz 526-7. PubMed ID: 21787195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.
    Annaloro C; Serpenti F; Saporiti G; Galassi G; Cavallaro F; Grifoni F; Goldaniga M; Baldini L; Onida F
    Front Immunol; 2020; 11():569381. PubMed ID: 33552044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced-intensity allogeneic stem cell transplantation for patients whose prior autologous stem cell transplantation for hematologic malignancy failed.
    Fung HC; Cohen S; Rodriguez R; Smith D; Krishnan A; Somlo G; Sahebi F; Senitzer D; O'Donnell MR; Stein A; Snyder DS; Spielberger R; Bhatia R; Falk P; Molina A; Nademanee A; Parker P; Kogut N; Popplewell L; Vora N; Margolin K; Forman SJ
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):649-56. PubMed ID: 14569561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies.
    Lee MW; Yeon SH; Heo BY; Kwon J; Ryu H; Lee HJ; Yun HJ; Jo DY; Song IC
    Hematology; 2021 Dec; 26(1):96-102. PubMed ID: 33459581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.